Mucin-based targeted pancreatic cancer therapy.

Imagen de María del Pilar Torres-González
PDF versionPDF version
TítuloMucin-based targeted pancreatic cancer therapy.
Publication TypeJournal Article
Year of Publication2012
AutoresTorres, MP, Chakraborty, S, Souchek, J, Batra, SK
JournalCurr Pharm Des
Volume18
Issue17
Pagination2472-81
Date Published2012
ISSN1873-4286
Palabras claveAnimals, Antineoplastic Agents, Cancer Vaccines, Drug Resistance, Neoplasm, Genetic Therapy, Humans, Immunotherapy, Molecular Targeted Therapy, Mucins, Neoplasm Proteins, Pancreatic Neoplasms
Abstract

The prognosis of pancreatic cancer (PC) patients is very poor with a five-year survival of less than 5%. One of the major challenges in developing new therapies for PC is the lack of expression of specific markers by pancreatic tumor cells. Mucins are heavily Oglycosylated proteins characterized by the presence of short stretches of amino acid sequences repeated several times in tandem. The expression of several mucins including MUC1, MUC4, MUC5AC, and MUC16 is strongly upregulated in PC. Recent studies have also demonstrated a link between the aberrant expression and differential overexpression of mucin glycoproteins to the initiation, progression, and poor prognosis of the disease. These studies have led to increasing recognition of mucins as potential diagnostic markers and therapeutic targets in PC. In this focused review we present an overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies.

Alternate JournalCurr. Pharm. Des.
PubMed ID22372499
PubMed Central IDPMC3530894
Grant ListP50 CA127297 / CA / NCI NIH HHS / United States
P50 CA127297 / CA / NCI NIH HHS / United States
R01 CA078590 / CA / NCI NIH HHS / United States
R01 CA131944 / CA / NCI NIH HHS / United States
R01 CA131944 / CA / NCI NIH HHS / United States
R01 CA133774 / CA / NCI NIH HHS / United States
R01 CA133774 / CA / NCI NIH HHS / United States
R01 CA78590 / CA / NCI NIH HHS / United States
T32CA009479 / CA / NCI NIH HHS / United States
UO1 CA111294 / CA / NCI NIH HHS / United States